InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Lindmark Bertil, Directeur médical. Director active across 1 company, notably Galecto, Inc.. Aggregated, 3 filings have been logged. Split: 3 buys · 0 sell. Total volume traded: €46k. Activity tracked since 28 June 2021. The latest transaction was filed on 22 March 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations3 total
14,604 shares@ US$2.1661.9% of flowCommon StockSEC:0001209191-22-020683:0
Ideal exit: 17 Dec 2022 (T+270)
2,000 shares@ US$5.2619.1% of flowCommon StockSEC:0001209191-21-043464
Ideal exit: 25 Mar 2022 (T+270)
2,000 shares@ US$5.2619.1% of flowCommon StockSEC:0001209191-21-043464:0
Ideal exit: 25 Mar 2022 (T+270)
3 of 3 declarations
About Lindmark Bertil
Bertil Lindmark is the Chief Medical Officer at Galecto, Inc. He is responsible for medical strategy and oversight of clinical operations. His role is essential in ensuring that Galecto adheres to medical and ethical standards.
